Facebook Twitter LinkedIn Google Plus RSS

Edge Therapeutics raises $18M million for drug development

By ,

Edge Therapeutics Inc., a clinical-stage biopharmaceutical company in New Providence, announced today it has raised $18 million in a Series C financing.

Edge said in the announcement it plans to use the proceeds to fund a Phase 2 study of its lead drug candidate, a treatment for the prevention of delayed cerebral ischemia. According to the announcement, Maxim Group LLC was the sole placement agent and financial adviser for the offering.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy